This bill requires Medicaid and CHIP programs to cover tobacco cessation counseling and FDA-approved medications (including nonprescription options) with no out-of-pocket costs for enrollees. It directly affects low-income individuals using tobacco products who are enrolled in Medicaid or CHIP. Key mechanisms include a temporary 90% federal funding share for these services for five years, prohibitions on prior authorization for cessation drugs, and requirements for states to promote these services through outreach campaigns. The law also mandates states to monitor and increase awareness of these covered benefits among tobacco users and healthcare providers.
The ASSIST Act (S 2050) increases federal funding for mental health and substance use disorder services provided in schools and school-based health centers. It raises the federal medical assistance percentage (FMAP) for these services to 90% for states, starting one year after enactment, while ensuring this doesn’t reduce existing federal payments or count against territorial spending limits. The bill also creates a new grant program administered by the Health and Human Services Secretary to fund entities like school districts and universities in hiring more licensed mental health providers, requiring culturally competent care and annual reporting on provider numbers and service effectiveness. It prohibits using grant funds for threat assessment teams and mandates a report to Congress on the program’s effectiveness within 18 months.
This bill expands Medicare coverage for mental health services provided to seniors in skilled nursing facilities. It removes a current exclusion, allowing clinical social workers to provide covered mental health services under Medicare Part A. Specifically, it adds coverage for a defined set of mental health and behavioral assessment services (using standard codes) that were previously excluded. The changes will take effect for services provided on or after January 1, 2026, directly benefiting seniors residing in skilled nursing facilities seeking these mental health services.
HRES 342 is a symbolic resolution recognizing the harmful history of diethylstilbestrol (DES), a drug prescribed to 5-10 million pregnant women in the U.S. from the 1940s until 1971 to prevent miscarriages. It urges the House to designate an awareness week for DES, acknowledge the drug’s link to rare cancers in children (known as "DES Daughters"), and call for restoring funding for the DES Follow-Up Study and a formal FDA apology to affected families. The resolution does not create new laws or directly affect anyone but formally documents the harm caused by DES and the FDA’s lack of accountability. It focuses on commemoration and urging action, not policy changes.
The Break Up Big Medicine Act requires large healthcare companies that own multiple parts of the healthcare system (such as insurance, pharmacies, and physician practices) to divest certain businesses to eliminate conflicts of interest. It prohibits common ownership between entities like health insurers and physician practices, or drug wholesalers and medical providers, mandating divestiture within one year of enactment. Non-compliance would trigger penalties including monthly escrow of 10% of profits, and the bill allows government agencies and individuals to sue for violations. This directly affects the largest health insurance companies, pharmacy benefit managers, and drug distributors that have integrated operations across the healthcare sector.
This bill expands Medicare coverage to include certain pharmacist services in medically underserved areas. It allows pharmacists licensed in their state to provide services that would otherwise be covered if done by a physician (like medication management), specifically in health professional shortage areas or medically underserved regions. Medicare would pay 80% of the physician fee schedule rate for these services, starting January 1, 2027. The bill requires the development of new billing codes for pharmacists under Medicare's physician fee schedule. It directly affects pharmacists working in designated underserved communities and Medicare beneficiaries there.
The Resident Physician Shortage Reduction Act of 2025 adds 14,000 new residency training positions over seven years (2027-2033), distributing 2,000 annually through a structured application process. It directly affects hospitals applying for these positions, requiring them to commit to filling the new spots and prioritizing rural hospitals, those serving health shortage areas, and hospitals affiliated with historically Black medical schools. Key mechanisms include seven annual application rounds, rules for carrying over unused positions, and minimum distribution quotas (e.g., 10% to rural hospitals). The bill also mandates a study on increasing diversity in the health workforce, with a report due to Congress within two years.
HR 4104 would expand access to Medicaid, CHIP, and Affordable Care Act (ACA) health coverage for immigrants lawfully present in the U.S., including those with deferred action or pending immigration applications. It removes state-level barriers to Medicaid/CHIP eligibility for lawfully present individuals, treats Federally authorized presence as "lawfully present" for ACA subsidies, and allows states to choose to cover undocumented individuals through Medicaid or CHIP. The bill also extends these changes to Medicare Part A and Part B, ensuring lawfully present immigrants qualify for coverage and subsidies under existing programs. These provisions apply to all federally funded health programs and take effect in 2026 for most ACA-related changes.
The PROTECT for Rare Act (S 3551) requires Medicare, Medicaid, and private health insurers to establish an expedited appeal process for coverage denials of drugs treating rare diseases or conditions affecting 200,000 or fewer U.S. individuals. It expands coverage criteria by allowing insurers to consider peer-reviewed medical literature and clinical guidelines - not just FDA-approved labeling - as valid justification for treatment, while excluding uses listed as contraindicated in approved drug labeling or medical references. The law applies to all covered drugs used for rare conditions and takes effect for coverage decisions starting January 1, 2027. This directly affects patients with rare diseases, healthcare providers seeking coverage approvals, and insurers managing drug benefit denials.
HR 3532, the Striking and Locked Out Workers Healthcare Protection Act, prohibits employers from terminating or altering an employee’s employer-sponsored health coverage during a lawful strike or a lockout (when an employer withholds work to influence bargaining). It directly affects workers participating in strikes or facing lockouts, ensuring continued healthcare access during these labor disputes. The bill adds penalties: $75,000 per violation for lockout-related coverage termination (up to $150,000 for repeat offenses), and $50,000 per violation for strike-related termination (up to $100,000 for repeat offenses), with penalties applied alongside other remedies. These provisions amend the National Labor Relations Act to protect workers’ healthcare rights during collective bargaining actions.
